netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Medi found 115 matches

Formulary items 52 matches
Sub Section Title / notes 14  matches
   
Open monograph to display formulary status BNF Category
  Betamethasone (as valerate) Medicated plasters  (Betesil®) Skin - Potent - 13.04
  Lidocaine 5% Medicated plasters (700mg lidocaine/plaster) Central nervous system - Postherpetic neuralgia - 04.07.03
  Medi Derma® S
(Barrier Cream) 		Wound Care - Other Wound Products - 18.10
  Medi Derma® S
(Barrier Film) 		Wound Care - Other Wound Products - 18.10
  Medi Derma-Pro Foam & Spray Skin Cleanser And Skin Protectant Ointment   (Medi Derma-Pro Foam & Spray Skin Cleanser®) Skin - Barrier preparations - 13.02.02
  Medi Derma-S barrier film   (Medi Derma-S ®barrier film) Skin - Barrier preparations - 13.02.02
  Medi® hosiery
(UNDER REVIEW) 		Wound Care - Graduated compression hosiery - 18.09.01
  Mediscrub® Skin - Cationic surfactants and soaps - 13.11.03
  NaldeMedine  (Rizmoic®) Gastro-intestinal system - Peripheral opioid-receptor antagonist - 01.06.06
  Acetylcysteine
(Mucolytic) 		Respiratory system - Mucolytics - 03.07
  Algivon® Wound Care - Sheet dressing - 18.03.01
  Anusol ® Gastro-intestinal system - Soothing haemorrhoidal preparations - 01.07.01
  Anusol®HC
(Ointment / Suppositories) 		Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Artificial Saliva Ear, nose and oropharynx - Treatment of dry mouth - 12.03.05
  Brinzolamide 10mg/ml & brimonidine 2mg/ml  (Simbrinza®) Eye - Carbonic anhydrase inhibitors and systemic drugs - 11.06
  Capreomycin Infections - Antituberculosis drugs - 05.01.09
  Cefazolin Infections - Cephalosporins - 05.01.02.01
  Chlorhexidine Ear, nose and oropharynx - Mouthwashes, gargles, and dentifrices - 12.03.04
  Clozapine Central nervous system - Second Generation Antipsychotic Drugs - 04.02.01
  Controlled Drug Dihydrocodeine Central nervous system - Opioid analgesics - 04.07.02
  Estradiol valerate plus dienogest  (Qlaira®) Obstetrics, Gynaecology, and urinary-tract disorders - Combined hormonal contraceptives - 07.03.01
  Gadobutrol  (Gadovist®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Gadoxetic acid  (Primovist®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Gastrografin Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Glucagon Endocrine system - Treatment of hypoglycaemia - 06.01.04
  Haemorrhoid relief ointment Gastro-intestinal system - Soothing haemorrhoidal preparations - 01.07.01
  Cytotoxic Drug Hydroxycarbamide Malignant disease and immunosuppression - Hydroxycarbamide - 08.01.05
  Imiquimod 5% cream  (Aldara®) Skin - Anogenital warts - 13.07
  Iopanoic acid Endocrine system - Antithyroid drugs - 06.02.02
  Ivermectin Skin - Scabies - 13.10.04
  L-Mesitran® Ointment Wound Care - Honey-based topical application - 18.03.01
  L-Mesitran® Ointment S Wound Care - Honey-based topical application - 18.03.01
  Meglumine gadoterate  (Dotarem®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Controlled Drug Methylphenidate Central nervous system - CNS stimulants and other drugs used for attention deficit hyperactivity disorder - 04.04
  Midazolam Anaesthesia - Benzodiazepines - 15.01.04.01
  Controlled Drug Morphine Central nervous system - Opioid analgesics - 04.07.02
  Oxybutynin Obstetrics, Gynaecology, and urinary-tract disorders - Urinary incontinence - 07.04.02
  Controlled Drug Oxycodone Central nervous system - Opioid analgesics - 04.07.02
  Phenazone with lidocaine  (Otigo®) Ear, nose and oropharynx - Otitis media - 12.01.02
  Potassium Iodate 85mg tablets Endocrine system - Antithyroid drugs - 06.02.02
  Proctosedyl® Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Quetiapine Central nervous system - Second Generation Antipsychotic Drugs - 04.02.01
  Rituximab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Rivastigmine Central nervous system - Drugs for dementia - 04.11
  Ruxolitinib Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
  Salbutamol Respiratory system - Short-acting beta2 agonists - 03.01.01.01
  Scheriproct®
(Ointment / Suppositories) 		Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Simeticone  (Infacol® Dentinox®) Gastro-intestinal system - Simeticine alone - 01.01.01
  Sodium Fluoride Nutrition and blood - Fluoride - 09.05.03
  Spironolactone Cardiovascular system - Aldosterone antagonists - 02.02.03
  Strontium Ranelate
(Sachets) 		Endocrine system - Strontium renelate - 06.06.02
  Ulipristal  (Esmya®) Endocrine system - Progestogens - 06.04.01.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Clinical Commissioning Policy: Pasireotide diaspartate: an injectable medical therapy for the treatment of Cushings’ Disease (08.03.04.03)
link in drug section DHSC Medicine Supply Notification - Permethrin 5% w/w cream (13.10.04)
link in drug section MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions (05.04.01)
link in drug section MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions (05.04.01)
link in drug section MHRA Drug Safety Alert (Oct 2017): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows’ milk allergy  (06.03.02)
link in drug section MHRA Drug Safety Update (Dec 2014): Smoking and smoking cessation: clinically significant interactions with commonly used medicines (03.01.03)
link in drug section MHRA Drug Safety Update (December 2014) Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose (08.01.05)
link in drug section MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)
link in drug section MHRA Drug Safety Update (February 2024): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine (03.09.01)
link in drug section MHRA Drug Safety Update (Jan 2019): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines (04.07.02)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (08.01.03)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (05.02.03)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (08.01.02)
link in drug section MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic (13.05.01)
link in drug section MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic (13.05.02)
link in drug section MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women (13.05.02)
link in drug section MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women (13.05.01)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.01)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.03)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.02)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05)
link in drug section MHRA Drug Safety Update (March 2014): Orlistat: theoretical interaction with antiretroviral HIV medicines (04.05.01)
link in drug section MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)
link in subsection MHRA Drug Safety Updates: Antiretroviral Medicines (05.03.01)
link in drug section NICE NG144: Cannabis-based medicinal products (10.02.02)
link in subsection NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (Master)
link in subsection NICE NG233: Otitis media with effusion in under 12s (12.01.02)
link in subsection NICE NG91: Otitis media (acute): antimicrobial prescribing (12.01.02)
link in drug section NICE TA651 - Naldemedine for treating opioid-induced constipation (01.06.06)
link in drug section NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (08.01.05)
link in subsection North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines (06.01)
link in drug section RCPCH & NPPG Position Statement - Using Standardised Concentraions of Unlicensed Liquid Medicines in Children  (09.02.01.02)
link in drug section RCPCH Position Statement: Using Standardised Concentrations of Liquid Medicines in Children (02.02.03)
link in drug section Regional Medicines Optimisation Committee (RMOC) Position Statement Oral vitamin B supplementation in alcoholism - November 2019 (09.06.02)
link in subsection TEWV - Medicines Optimisation – Interactive Guide (Master)
link in drug section TEWV Depression medication pathway for adults (04.03.04)
link in subsection TEWV Depression medication pathway for adults (04.03)
link in subsection TEWV: Anxiety medication pathway for adults (04.01.02)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.07.04.02)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.08.01)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.02.03)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.02.03)

SubSection Titles / notes  
Antifungals - (11.03.02)
Antipsychotic Drugs - (04.02.01)
Contact lenses - (11.09)
Emollient bath and shower preparations - (13.02.01.01)
InterMediate- and long-acting insulins - (06.01.01.02)
Medicated bandages - (18.08.09)
Medicated stocking - (18.08.09)
MRI Contrast Media - (19)
Neuropathic pain - (04.07.03)
Opioid analgesics - (04.07.02)
Oral anticoagulants - (02.08.02)
Otitis Media - (12.01.02)
SomatoMedins - (06.07.04)
Sunscreen preparations - (13.08.01)

 
netFormulary